×
About 653 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  231 results

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report fro...
https://doi.org/10.1182/blood.2020010387
Blood Advani RH, Skrypets T et. al.

Jul 23rd, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018...

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment.
https://doi.org/10.1097/CCO.0000000000000773
Current Opinion in Oncology; Tari G, Lemonnier F et. al.

Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent peripheral T-cell lymphoma affecting elderly patients with a poor outcome when treated with conventional chemotherapy. Molecular studies revealed a homogenous mutational landscape gathering a...

How I Diagnose Angioimmunoblastic T-Cell Lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209595
American Journal of Clinical Pathology; Xie Y, Jaffe ES

Jun 13th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma derived from T-follicular helper cells. For pathologists, diagnosing AITL may be challenging due to its wide clinical and histopathologic spectrum, which can mimi...

A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161901
The Journal of International Medical Research; Sun J, He S et. al.

May 27th, 2021 - To explore prognostic factors and develop an accurate prognostic prediction model for angioimmunoblastic T-cell lymphoma (AITL). Clinical data from Chinese patients with newly diagnosed AITL were retrospectively analysed. Overall survival (OS) and...

see more →

Clinicaltrials.gov  10 results

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

May 4th, 2020 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of MEDI-570 (anti-ICOS monoclonal antibody MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.
https://clinicaltrials.gov/ct2/show/NCT02464228

Mar 4th, 2020 - This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. The first 18 subjects may be of the following PTCL sub-types: PTCL not otherwise specified (PTCL-NOS), angioimm...

Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02561273

Sep 10th, 2019 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...

A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms
https://clinicaltrials.gov/ct2/show/NCT03493451

Sep 10th, 2018 - This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in patients with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two coh...

Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02424045

Sep 6th, 2018 - Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of nodal and extranodal mature T-cell lymphomas, which constitute about 5 - 10% of all non-Hodgkin lymphomas (NHLs) in Western countries compared to 20 - 30% of all lymphomas in th...

see more →

News  20 results

T-cell lymphoma registries: What have we learned?
https://www.mdedge.com/hematology-oncology/article/207981/t-cell-lymphomas/t-cell-lymphoma-registries-what-have-we-learned?channel=39313
Jennifer Smith

Sep 11th, 2019 - Registries for T-cell lymphoma have improved our understanding of the disease, but many questions remain. Could combining the various registries provide more answers? “[T]here are many, many different registries around the world,” said Owen O’Conn.

Angioimmunoblastic T-cell Lymphoma: Patient Characteristics and Survival Outcomes
https://www.mdedge.com/fedprac/avaho/article/207820/lymphoma-plasma-cell-disorders/angioimmunoblastic-t-cell-lymphoma?channel=53
Ermann DA, Vardell VA et. al.

Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
https://www.mdedge.com/hematology-oncology/article/193975/lymphoma-plasma-cell-disorders/cerdulatinib-yields-encouraging?channel=39313
Jennifer Smith

Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.

Combo emerges as bridge to transplant in rel/ref PTCL
https://www.mdedge.com/hematology-oncology/article/193912/lymphoma-plasma-cell-disorders/combo-emerges-bridge-transplant/page/0/1?channel=39313

Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.

see more →